ASRS 2024: Industry updates and new research findings expected at this year's meeting


A preview of presentations from 4D Molecular Therapeutics and Adverum Biotechnologies

An aerial photo of Stockholm, Sweden. Image credit: ©Kavalenkava –

As the 2024 ASRS meeting draws nearer, companies in the retina space are previewing their presentations. Image credit: ©Kavalenkava –

The American Society of Retina Specialists (ASRS) is set to host its 2024 annual meeting in Stockholm, Sweden, from 16-20 July. This event brings together retina specialists from around the globe to discuss cutting-edge research, provide updates on clinical trials and network with one another.

The meeting also serves as a launchpad for industry news as companies relay results from ongoing studies. As the 2024 ASRS meeting draws nearer, companies in the retina space are beginning to highlight the presentations where they plan to showcase major news.

Throughout the weeks leading up to the conference, the Modern Retina team will highlight industry announcements and share that news with the rest of the Eye Care Network. First, two previews of upcoming data from 4D Molecular Therapeutics and Adverum Biotechnologies.

4D Molecular Therapeutics

4D Molecular Therapeutics will present the initial interim 24-week landmark analysis from the population extension cohort of the PRISM Phase 2 Clinical Trial evaluating 4D-150. This potential treatment is being evaluated for a broad wet AMD patient population.1

The presentation, entitled “Phase 2 Population Extension Cohort in the PRISM Trial Evaluating 4D-150 in Adults with Neovascular Age-related Macular Degeneration,” will take place Wednesday, 17 July, 2024 at 8:49-8:53 am (CEST). The findings will be presented by Raj K. Maturi, MD from Midwest Eye Institute & Retina Partners Midwest, Indianapolis, IN.1

Adverum Biotechnologies

Charles C. Wykoff, MD, PhD, FASRS, the Director of Research at Retina Consultants of Texas; Professor of Clinical Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, will present, “Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study.” This presentation will take place on Wednesday, 17 July, at 8:45 am (CEST).2


1. 4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast. 4D Molecular Therapeutics. Published June 18, 2024. Accessed June 25, 2024.
2. Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting. Adverum Biotechnologies, Inc. Published April 25, 2024. Accessed June 25, 2024.

Recent Videos
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
© 2024 MJH Life Sciences

All rights reserved.